Ian Butterworth
CTO & Co-founder, Leuko

SENSE.nano 2021
Tuesday, October 26
Session:  Startups
1:00 PM - 1:05 PM EDT

Abstract
Leuko is developing PointCheck, the first device to provide noninvasive neutropenia screening in the home, set to improve safety, efficacy and economics for chemotherapy. Started by Leuko's co-founders in the MIT M+Vision/LinQ programme, since spinning out, Leuko has been developing PointCheck with the support of developmental usability and performance studies at sites including the MIT CRC, to ensure a product that meets regulatory requirements around performance and usability, and is set to make impact.

Biography
A hardware and software engineer who started his career in measurement research at the UK’s National Physical Laboratory, developing new measurement techniques centered around audio, and industrial and medical ultrasonics. As a Research Engineer in the MIT M+Vision/LinQ biomedical innovation programme Ian co-created projects centered around unmet medical needs, leading hardware and software development of a rich variety of measurement device prototypes, leading to the spin-out of several companies, including Leuko. Now Chief Technology Officer and Co-founder of Leuko, Ian is driving the development of the PointCheck product through R&D, studies, and design for manufacturing.